What the JAMA Ophthalmology research on semaglutide actually found

The misconception doing the rounds: semaglutide has been proven to damage eyesight

That claim overstates what the research actually demonstrated. The JAMA Ophthalmology paper (published in July 2024, led by researchers at Mass Eye and Ear in Boston) found that people with obesity or type 2 diabetes who were prescribed semaglutide had a statistically higher rate of NAION diagnoses compared with those prescribed other medicines for the same conditions. In the obesity cohort, the researchers reported roughly 8.9 NAION cases per 10,000 patients on semaglutide versus 1.8 per 10,000 in those taking non-GLP-1 alternatives.

Those numbers sound striking. But the study was retrospective, meaning it looked back at existing health records rather than running a controlled experiment. Retrospective observational research cannot rule out confounding: the groups of patients who received semaglutide may have differed from comparison groups in ways that influenced their NAION risk independently of the drug. The researchers themselves flagged this explicitly, calling for prospective studies. Describing the paper as proof of causation misreads both the methodology and the authors' own conclusions.

NAION itself is serious but rare. It occurs when blood supply to the optic nerve is briefly compromised, and it tends to occur in people who already have risk factors, small optic disc anatomy, high blood pressure, diabetes, sleep apnoea, high cholesterol. Many of these overlap with the conditions semaglutide is prescribed to treat, which makes disentangling cause and association genuinely difficult. You can read a full overview of what semaglutide is and how it is used, which helps put that complexity in context.

What UK regulators have and have not said

The MHRA, which licenses medicines in the UK, has not issued a Drug Safety Update restricting semaglutide's use on the basis of the JAMA Ophthalmology findings. The medicine's existing patient information already advises people to seek prompt medical attention for sudden changes in vision, particularly in the context of diabetic retinopathy, a separate, well-established eye complication of diabetes that semaglutide's labelling already references.

Regulatory agencies do not wait for certainty before acting; they act on reasonable evidence of risk. The absence of a restriction does not mean regulators are unaware of the study, it means the current risk-benefit assessment for the licensed population has not been overturned by it. The MHRA's Yellow Card scheme allows patients and clinicians to report suspected side effects at any time, and regulators continue to scrutinise the accumulating post-market data.

People with pre-existing optic nerve conditions, a history of NAION, or established risk factors for it should discuss those specifics with their prescriber before starting semaglutide. That is not a reason to avoid the medicine; it is a reason to have the conversation properly. A prescriber who knows your full medical history can weigh the evidence alongside your individual circumstances in a way that a newspaper headline simply cannot.

Sudden vision changes: what to do

Whatever the eventual conclusions of future prospective research, one practical point is not in dispute: sudden, painless loss of vision in one eye is a medical emergency regardless of what medicines you take. If that happens, call 999 or go straight to A&E. Do not wait to see if it resolves. Do not call the pharmacy first. This is listed in the NHS's patient-level guidance on semaglutide as one of the signs that requires urgent medical attention, alongside severe stomach pain, signs of pancreatitis, and allergic reactions.

More generally, any change in vision that appears while you are taking semaglutide (blurring, episodes of reduced clarity, anything that feels new or different) is worth mentioning to your prescriber at the next opportunity, even if it feels minor. For people managing diabetes alongside weight, regular eye screening is already recommended; continuing that screening makes sense on treatment. If you have questions about semaglutide and eye health that you want to put to a clinician directly, our support team is available seven days a week.

Putting this in the broader picture of semaglutide's safety record

Semaglutide has one of the largest bodies of clinical-trial evidence of any weight-management medicine available in the UK. The STEP 1 trial, involving nearly 2,000 adults with obesity, demonstrated around 15% average weight reduction over 68 weeks and is the foundation of the NICE recommendation (TA875) for Wegovy, the branded formulation approved for weight management in the UK. That trial, and the broader STEP programme, documented a side-effect profile dominated by gastrointestinal effects (nausea, constipation, indigestion) rather than eye complications.

The JAMA Ophthalmology finding is a legitimate signal that warrants proper investigation. It is not a verdict. Clinical medicine regularly involves weighing a known, quantified benefit against a possible, incompletely characterised risk, and the people best placed to make that call for a specific patient are clinicians who know them. Semaglutide is a prescription-only medicine for exactly this reason: every course of treatment starts with an individual clinical assessment, not a one-size policy. Our pages covering semaglutide 1mg dosing guidance, semaglutide 2mg dosing guidance, and semaglutide 3mg dosing guidance set out the side-effect considerations at each stage, and you can also explore the range of weight-loss treatment options that may be suitable, before deciding whether a consultation makes sense for you. One of our prescribers reviews every consultation personally (not software) on the same day it is submitted, usually well before the 12pm cut-off that triggers same-day dispatch.

If you would like to discuss your specific health background and whether semaglutide is appropriate for you, those conversations are also informed by how semaglutide works at a pharmacological level, including its receptor activity and metabolic effects, and speak to our prescribers through a free consultation.